an die CALY (CYPTV)-Fans/Kritiker/Besitzer
Seite 3 von 4 Neuester Beitrag: 13.08.05 02:01 | ||||
| Eröffnet am: | 30.05.03 10:42 | von: Kalli2003 | Anzahl Beiträge: | 84 |
| Neuester Beitrag: | 13.08.05 02:01 | von: BrokersGewi. | Leser gesamt: | 9.377 |
| Forum: | Hot-Stocks | Leser heute: | 5 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | | 4 > | ||||
--------------------------------------------------
Calypte Receives Another Order from Its Primary China Distributor for 150,000 Tests
ALAMEDA, Calif.--(BUSINESS WIRE)--June 26, 2003--Calypte Biomedical Corporation (OTCBB:CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has received an additional order for Urine HIV-1 EIA tests from its Chinese distributor, Zhong Yang Pute Co. ("ZYPute"), a distributor of medical products in China.
Calypte signed an exclusive two-year distributor agreement with ZYPute in October 2002. Calypte's first order from ZYPute for approximately 112,000 tests was shipped in December 2002 upon receipt of a Letter of Credit payment. The additional order, for 150,000 tests, was originally expected to ship in Q1, 2003. However, the Chinese SARS problem that was emerging at that time created widespread disruptions both in the normal delivery of healthcare, as well as in distribution logistics. Now that the SARS problem has dissipated, ZYPute has requested that the shipment proceed.
Jay Oyakawa, President and COO of Calypte, stated, "Clearly it has been a challenge to maintain momentum in light of the difficulties created by SARS, but we are pleased to acknowledge the hard work that ZYPute is doing in China. Together, our two companies are working very closely to achieve success in a market characterized both by unique opportunities and challenges."
About Calypte Biomedical
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. When compared with existing blood-based tests, our testing algorithms are non-invasive, easier to use, less expensive and have significantly less risk than blood-based testing, and they have 99.7% sensitivity in subjects previously identified as HIV-1 infected and 100% specificity in subjects at low risk when combined with the urine-based Western Blot supplemental test(a). The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
(a) "The performance of testing urine samples for HIV-1 antibodies is reduced in some populations in comparison to testing blood. Please refer to the product inserts for details."
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Company Contact: Richard VanMaanen, 613/728-3130 email:dvanmaanen@calypte.com www.calypte.com
SOURCE: Calypte Biomedical Corporation
ALAMEDA, Calif.--(BUSINESS WIRE)--June 25, 2003--Calypte Biomedical Corporation (OTCBB:CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has appointed Enfield Medical Co. Ltd. as its exclusive distributor for Taiwan.
Enfield is a Taipei-based company, acknowledged as one of the top ten medical product importers in the country. Enfield Medical was founded in 1988, and actively markets a number of premium global brands of healthcare products. Enfield is a subsidiary of Excelsior Healthcare Group whose alliances include hospitals, IT services, logistic and inventory management, performance improvement and E-commerce.
"With the appointment of Enfield, we have successfully, and meaningfully expanded our Asian presence," said Tony Cataldo, Calypte's Executive Chairman.
Richard VanMaanen, Director of International Business Development at Calypte, stated, "As with all of Calypte's urine HIV distribution agreements, Enfield's rights are exclusive within its territory, and Enfield has specific obligations regarding minimum purchases during the agreement. We are eager to work with Enfield in obtaining all of the requisite registrations, and to promoting safer and more patient-friendly approaches to HIV testing for their country."
Jack Chen, CEO and Chairman of Enfield, said, "We have been providing state of art medical products to Taiwan for 25 years, and Calypte's products will meet people's prevention needs here in Taiwan."
Statistics released in November 2002 by the Taiwanese Department of Health estimated a cumulative total of approximately 4,500 HIV cases -- a 16% increase over the previous year. Roughly three quarters of the new infections occurred in young people aged between 20 and 39 years. In response to the statistics, the Department of Health has targeted 2006 as the year in which Taiwan must achieve a zero growth rate in new infections.
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. When compared with existing blood-based tests, our testing algorithms are non-invasive, easier to use, less expensive and have significantly less risk than blood-based testing, and they have 99.7% sensitivity in subjects previously identified as HIV-1 infected and 100% specificity in subjects at low risk when combined with the urine-based Western Blot supplemental test(a). The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
(a) "The performance of testing urine samples for HIV-1 antibodies is reduced in some populations in comparison to testing blood. Please refer to the product inserts for details."
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation Richard VanMaanen, 613/728-3130 dvanmaanen@calypte.com or Sitrick And Company Joe Bunning, 310/788-2850 (investor relations) joe_bunning@sitrick.com
SOURCE: Calypte Biomedical Corporation
150.000 Tsd. Tests ? Wieviel verdienen die an 1 Stück ? 1$ oder 2$ ???
Die Meldungen ändern nichts an meiner Skepsis.
ist die Nancy Katz schon mal weg !!!
Deshalb sollte der Kurs sinken, aber nicht bei Caly, hihihi !!!
Ich kann nur noch lachen, denn die Aktie hat was, *ggggg
Mein heutiger Tipp für Amiland 0,32 USD aber danach kann ich für nichts garantieren !!!
So long,
Calexa
www.investorweb.de
vielleicht mal du alter schwarzmaler, hehehe, im Mai sollte Calypte schon Pleite sein, weißt du wohl gar nicht mehr, die Zeit heilt die Wunden und dann lecken wir
unsere Dollarchen, *ggg
gruß werweiß
lieber gut träumen als schlecht leben
So long,
Calexa
www.investorweb.de
Jetzt werden extra noch zwei Veteranen dazu eingestellt. Welche Produkte sind denn jetzt marktreif(angeblich ja auch mit Genehmigung der FDA) und welche müssen erst noch weiterentwickelt werden?
Calypte Announces Dr. J. Richard George to Head Its Rapid HIV Business
Monday June 30, 9:02 am ET
ALAMEDA, Calif.--(BUSINESS WIRE)--June 30, 2003--Calypte Biomedical
Corporation (OTCBB:CYPT - News):
Dr. George, former Senior VP of Infectious Disease Research and
Development at OraSure Technologies, Inc., and a 30-Plus Year Veteran
of the Centers for Disease Control and Prevention
Dr. Ronald Mink to Co-Lead Calypte's Rapid Business
Calypte Biomedical Corporation (OTCBB:CYPT - News), the developer and
marketer of the only two FDA approved HIV-1 antibody tests for use with urine
samples, announced today changes in personnel assignments in its effort to
develop rapid HIV assays for the U.S. and international markets.
Recent decisions by the Centers for Disease Control and Prevention, the Food
and Drug Administration, and other HIV Prevention agencies have clearly
identified antibody testing as a key component of the effort to reduce the
incidence of HIV infections both in the United States and worldwide. Further, the
quick approval by FDA and acceptance of two blood rapid HIV-1 tests provide
convincing evidence that rapid tests will be important tools in these programs.
Calypte Biomedical has rapid assays under development for the sensitive and
specific detection of HIV antibodies that are present in both urine and whole
blood of infected individuals. Calypte is committed to the rapid development
and introduction of these tests into the worldwide market. To this end, Calypte
has assembled an experienced and capable team of scientists to successfully
complete this project. Leading the effort is Dr. J. Richard George, former Senior
VP of Infectious Disease Research and Development at OraSure Technologies,
Inc., and a 30-plus year veteran of the Centers for Disease Control and
Prevention. While at OraSure, Dr. George had oversight responsibility for the
research and development of all infectious disease products (including its
OraQuick HIV-1 rapid product), domestic and international research
collaborations, and clinical trials for this rapid device. Dr. George stated, "I am
excited and honored to be selected to direct the efforts of this skilled group of
scientists to again produce an important test for containing the spread of HIV."
Co-leader for the project is Dr. Ronald W. Mink, former Director of Research
and Development at OraSure Technology. Dr. Mink has 20-plus years of
experience in the development and commercialization of rapid assays at such
companies as Quidel and Carter Wallace. Dr. Mink was the inventor of the first
OraQuick HIV-1 rapid prototypes (U.S. Patent 6,303,081). Dr. Mink supervised
the OraQuick research and development effort and oversaw product transfer to
production. Dr. Mink's skills and experience will contribute significantly to
shortening the time for introduction of the Calypte rapid HIV tests.
When available, the rapid Calypte urine tests will provide non-invasive
alternatives to blood and will enable Public Health Agencies to use testing
algorithms composed of multiple rapid tests capable of providing a final test
result in outreach settings.
"The experience that both Dr. George and Dr. Mink bring to the company with
their proven track records of delivering rapid test technologies to market, along
with our new President and COO, Jay Oyakawa, gives us a strong management
team to position the company as a leader in Rapid HIV testing," said Anthony
Cataldo, Executive Chairman of Calypte Biomedical.
Jay Oyakawa, President and COO of Calypte, stated, "In many settings both
here in the United States as well as abroad, rapid tests offer some specific
advantages over laboratory-based testing. We intend to capitalize on those
advantages by developing rapid blood and urine tests that meet our customers'
needs, both in terms of price and performance. We are dedicated to putting all
of the necessary resources behind that goal. At the same time, we will continue
to support all of those customers who have come to rely upon our original
FDA-approved urine HIV-1 testing algorithm for batch-based testing."
Natürlich wird die Aktie irgendwan mal wieder 20% 60% vielleicht auch 200% aber an die Zukunft glaube ich nicht mehr. Bei diesem Unternehmen hat die Mafia die Hand im Spiel, Meldungen nacheinander und der Kurs singt, habt ihr noch nichts bemerkt ???
Andauernd kommen neue Pakete auf dem Markt, die sofort zu jedem Kurs verkauft werden.
Wenn Calypte so gut wäre würde diese Leute niemals und nochmal NIEMALS die Dinger verkaufen.
Wir sind reingefallen und müssen es jetzt zugeben !!!!!!!!!!!
ADE BÖRSE und verflucht sollen diese Betrüger auf Lebenszeit sein, möge ihnen der Champus aus der Nase fliessen.
Die Welt dreht weiter,nicht runter kriegen KOPF HOCH.
CIAO
der war dein bester, aber ansonsten, Caly ist halt risiko das war mir schon immer klar, heute und in den nächsten tagen kommt die erholung, wer wettet mit !!!
gruß werweiß
Wohl eher nicht wenn ich die letzten Tage ca 50% verloren hab!!!
Hört auf euch es schön zureden...........
So long,
Calexa
www.investorweb.de
Tüddeldü leutz
ich weiß genau so viel wie du, nichts da hast du recht, entweder oder ist die Devise
also warts ab und wenn du recht hast dann darfst du lästern, ich mach das nicht so ist halt mein Charakter, also lieber Taodon, immer schön kurz halten,
denn keiner ist allwissend !!!!
auch nicht du
gruß werweiß
investieren 12.600.000 $ in calypte.
Siehe SEC Filings, wenn ich mich nicht ihre,
könnt mich gerne eines besseren belehren, aber ich glaub ich hab recht !!!
Thursday July 10, 8:31 am ET
- DeYi Corporation Expands Calypte Coverage to Include 28 Provinces in China -
ALAMEDA, Calif., July 10 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT - News), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has appointed DeYi Corporation as its exclusive distributor for eight provinces of China that are not covered by the Company's previously appointed China distributor, Zypute.
ADVERTISEMENT
DeYi is a Beijing-based company that specializes in the distribution of in vitro diagnostic assays. In addition to its IVD distribution activities, DeYi also operates its own clinic and reference laboratory in Beijing, and intends to use the urine test in that setting. DeYi has placed its first order with Calypte, which is due for shipment in the third quarter of 2003, after product training has taken place.
"With the appointment of DeYi, we now have agreements with two major distributors that cover virtually all of China," said Tony Cataldo, Calypte's Executive Chairman. "We know that the current SARS situation in China has impacted all facets of their healthcare delivery system recently, but now that this situation seems to be normalizing, we will be well positioned to meet the growing demand for HIV-1 antibody tests in China."
Richard Van Maanen, Director of International Business Development at Calypte, stated, "As with all of Calypte's urine HIV distribution agreements, DeYi's rights are exclusive within its territory, and DeYi has specific obligations regarding minimum purchases during the term of the agreement. Our two Chinese distributors cover distinct and non-competing territories."
Ich dachte die Amis würden ihre Aktiengesselschaften härter Kontrollieren !